CRISPR Therapeutics (CRSP) said Thursday that new phase 1 clinical data for its treatment CTX310 continues to demonstrate dose-dependent reductions in triglycerides and low-density lipoprotein, which are recognized risk factors for atherosclerotic heart disease.
The data showed peak reduction of up to 82% in triglycerides and up to 86% in low-density lipoprotein, with a well-tolerated safety profile, the company said.
CRISPR said it expects to present complete phase 1 data of CTX310, which targets the ANGPTL3 gene, at a medical meeting in H2.
The company said it also expects an update for its phase 1 trial of CTX320 in H1 2026. The investigational treatment targets the LPA gene in patients with elevated lipoprotein, a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.